No surprise that advertising costs have offset gains in sales over the last two quarters but revenues are up 8% from the comparable quarter last year. I think it may be a few more quarters before the sales of Oraquick no longer depend on as much advertising expense as has been the case to date. That said, I think the next few days of trading will be interesting.
Management has had more than sufficient time to get this HIV product up and running. In my opinion, it should be flying off the shelves by now. Instead, the increased sales volume is low, and the advertising expense is high. I am not sure this management team could find their way out of a paper bag. Very disappointing. I sure wish I never caught that interview on CNBC with their CEO about a year ago.